Vimarsana
Biggest News Aggregation in the World

Page 10 - Oncology Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Program Today - Breaking & Trending Today

HMC's Cardio-Oncology Program providing unique services to patients - Vimarsana News

HMC's Cardio-Oncology Program providing unique services to patients

Doha, Qatar: Hamad Medical Corporation s pioneering Cardio Oncology Program aims to become a beacon of excellence in the Middle East and beyond. The p...

EXCLUSIVE: Ocean Biomedical Unveils Comprehensive Updates On Its Cancer, Malaria, Fibrosis Programs - Ocean Biomedical (NASDAQ:OCEA) - Vimarsana News

EXCLUSIVE: Ocean Biomedical Unveils Comprehensive Updates On Its Cancer, Malaria, Fibrosis Programs - Ocean Biomedical (NASDAQ:OCEA)

Ocean Biomedical Inc (NASDAQ: OCEA) shared an update on its broad range of programs in malaria, fibrosis, and multiple cancers. Oncology Program:

Veru Reports Fiscal 2023 Third Quarter Financial Results - Vimarsana News

Veru Reports Fiscal 2023 Third Quarter Financial Results

Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based... -Today at 06:31 am- MarketScreener

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress - Vimarsana News

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

- Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in...

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma - Vimarsana News

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma

David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.